Centessa (CNTA) Form 4: 593 shares withheld, 193,801 owned

Centessa Pharmaceuticals (CNTA) reported an insider equity update.

Rhea-AI Filing Summary

Centessa Pharmaceuticals (CNTA) reported an insider equity update. The company’s Officer (President, Orexin Program) filed a Form 4 showing a tax withholding transaction tied to vested restricted share units. On 11/01/2025, 593 Ordinary Shares were withheld under code F at $24.9 per share to satisfy taxes. Following this administrative withholding, the insider’s beneficial ownership is 193,801 Ordinary Shares, held directly. The filing notes each American Depositary Share currently represents one Ordinary Share.

Insider Trade Summary

Exercise Price or Tax Liability: 593 shares

Exercise Price or Tax Liability 1 txn

Insider Accardi Mario Alberto

Role President, Orexin Program

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Ordinary Shares	593	$24.90	$15K

Holdings After Transaction: Ordinary Shares — 193,801 shares (Direct)

Footnotes (2)

1. F1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
2. F2. Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.

FAQ

What did CNTA disclose in this Form 4?

An officer reported a tax withholding transaction (code F) related to RSU vesting, with 593 Ordinary Shares withheld at $24.9 per share.

How many CNTA shares does the insider now own?

Following the transaction, the insider beneficially owns 193,801 Ordinary Shares, held directly.

Was this an open‑market sale of CNTA shares?

No. Code F indicates shares were withheld to cover taxes upon RSU vesting, not an open‑market sale.

What was the transaction date and price?

The transaction occurred on 11/01/2025 at a price of $24.9 per share.

Who is the reporting person’s role at Centessa (CNTA)?

The reporting person is an Officer, titled President, Orexin Program.

How do CNTA ADS relate to Ordinary Shares?

Each American Depositary Share currently represents one Ordinary Share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/03/2025 - 04:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Accardi Mario Alberto

(Last) (First) (Middle)

C/O CENTESSA PHARMACEUTICALS PLC

3RD FL., 1 ASHLEY RD, ALTRINCHAM

(Street)

CHESHIRE X0 WA14 2DT

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Centessa Pharmaceuticals plc [ CNTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, Orexin Program

3. Date of Earliest Transaction (Month/Day/Year)
11/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	11/01/2025		F		593(2)	D	$24.9	193,801	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.

Remarks:

	/s/ Raphael Deferiere, attorney-in-fact	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.